share_log

Medical Properties Trust Analyst Ratings

Benzinga ·  Oct 17, 2023 09:54
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/17/2023 -20.87% Wells Fargo $7 → $4 Maintains Underweight
10/16/2023 -20.87% Wells Fargo → $4 Downgrades Equal-Weight → Underweight
09/25/2023 97.82% RBC Capital → $10 Reiterates Outperform → Outperform
08/31/2023 78.04% Mizuho $18 → $9 Downgrades Buy → Neutral
08/22/2023 97.82% Barclays $12 → $10 Maintains Overweight
08/21/2023 38.48% JP Morgan $9 → $7 Downgrades Neutral → Underweight
08/14/2023 97.82% RBC Capital $12 → $10 Maintains Outperform
08/11/2023 58.26% B of A Securities $9 → $8 Downgrades Neutral → Underperform
08/11/2023 Raymond James Downgrades Strong Buy → Underperform
06/23/2023 97.82% Truist Securities $9 → $10 Maintains Hold
04/20/2023 78.04% Wells Fargo → $9 Initiates Coverage On → Equal-Weight
04/19/2023 78.04% Wells Fargo → $9 Initiates Coverage On → Equal-Weight
04/05/2023 137.39% Barclays $14 → $12 Maintains Overweight
04/04/2023 196.74% Keybanc $16 → $15 Maintains Overweight
03/31/2023 78.04% Truist Securities $8 → $9 Maintains Hold
03/29/2023 58.26% Truist Securities $14 → $8 Maintains Hold
03/16/2023 97.82% B of A Securities → $10 Downgrades Buy → Neutral
03/07/2023 117.61% Credit Suisse → $11 Reiterates → Neutral
03/03/2023 137.39% JP Morgan $14 → $12 Maintains Neutral
03/02/2023 216.52% Raymond James $18 → $16 Maintains Strong Buy
02/27/2023 176.95% Barclays $17 → $14 Maintains Overweight
02/24/2023 117.61% Credit Suisse $13 → $11 Maintains Neutral
01/27/2023 236.3% Barclays $19 → $17 Maintains Overweight
01/19/2023 216.52% Keybanc $18 → $16 Maintains Overweight
01/17/2023 157.17% Credit Suisse $11 → $13 Maintains Neutral
12/21/2022 117.61% Credit Suisse $17 → $11 Maintains Neutral
11/14/2022 216.52% B of A Securities → $16 Upgrades Neutral → Buy
10/21/2022 275.87% Barclays $23 → $19 Maintains Overweight
10/04/2022 256.08% RBC Capital $20 → $18 Maintains Outperform
09/22/2022 256.08% Raymond James $20 → $18 Maintains Strong Buy
09/16/2022 196.74% Deutsche Bank $17 → $15 Maintains Hold
08/04/2022 355% Barclays $27 → $23 Maintains Overweight
07/29/2022 295.65% Mizuho $26 → $20 Maintains Buy
07/15/2022 295.65% Raymond James $24 → $20 Maintains Strong Buy
07/14/2022 236.3% Credit Suisse $23 → $17 Downgrades Outperform → Neutral
07/13/2022 236.3% Deutsche Bank $20 → $17 Maintains Hold
07/07/2022 256.08% Keybanc $23 → $18 Maintains Overweight
06/30/2022 196.74% Jefferies $19 → $15 Maintains Hold
06/22/2022 256.08% JP Morgan $24 → $18 Downgrades Overweight → Neutral
05/20/2022 335.21% RBC Capital $25 → $22 Maintains Outperform
05/10/2022 374.78% Raymond James $26 → $24 Maintains Strong Buy
05/02/2022 355% Credit Suisse $26 → $23 Maintains Outperform
04/27/2022 295.65% Deutsche Bank $25 → $20 Maintains Hold
04/27/2022 355% Keybanc $24 → $23 Maintains Overweight
04/22/2022 295.65% Jefferies $25 → $20 Downgrades Buy → Hold
03/24/2022 355% Truist Securities $26 → $23 Maintains Hold
03/11/2022 B of A Securities Downgrades Buy → Neutral
02/14/2022 414.34% Credit Suisse $27 → $26 Maintains Outperform
02/01/2022 Credit Suisse Initiates Coverage On → Outperform
01/03/2022 394.56% Deutsche Bank $27 → $25 Downgrades Buy → Hold
10/29/2021 414.34% Raymond James $25 → $26 Maintains Strong Buy
10/27/2021 374.78% B of A Securities $21.5 → $24 Upgrades Neutral → Buy
10/26/2021 394.56% Raymond James → $25 Initiates Coverage On → Strong Buy
08/11/2021 355% RBC Capital → $23 Upgrades Sector Perform → Outperform
07/14/2021 355% Mizuho → $23 Assumes → Buy
07/06/2021 325.32% B of A Securities → $21.5 Downgrades Buy → Neutral
06/15/2021 355% Wolfe Research → $23 Initiates Coverage On → Peer Perform
05/03/2021 355% RBC Capital $24 → $23 Downgrades Outperform → Sector Perform
01/22/2021 335.21% Truist Securities → $22 Downgrades Buy → Hold
01/21/2021 374.78% KeyBanc $22 → $24 Maintains Overweight
12/15/2020 374.78% Deutsche Bank → $24 Upgrades Hold → Buy
09/02/2020 315.43% Stifel → $21 Reinstates → Buy
08/24/2020 355% Mizuho $20 → $23 Upgrades Neutral → Buy
07/10/2020 275.87% Deutsche Bank $23 → $19 Downgrades Buy → Hold
06/25/2020 295.65% SunTrust Robinson Humphrey $19 → $20 Maintains Buy
04/23/2020 275.87% SunTrust Robinson Humphrey $22 → $19 Maintains Buy
04/21/2020 295.65% Keybanc $25 → $20 Maintains Overweight
04/03/2020 216.52% Wells Fargo $21 → $16 Maintains Equal-Weight
04/03/2020 295.65% JP Morgan $25 → $20 Maintains Overweight
03/30/2020 275.87% Mizuho → $19 Downgrades Buy → Neutral
01/16/2020 355% Keybanc $22 → $23 Maintains Overweight
01/14/2020 335.21% Baird $20 → $22 Maintains Neutral
12/26/2019 414.34% Mizuho $25 → $26 Maintains Buy
12/20/2019 394.56% Mizuho → $25 Initiates Coverage On → Buy
10/14/2019 285.76% B of A Securities → $19.5 Initiates Coverage On → Neutral
09/12/2019 335.21% Berenberg → $22 Initiates Coverage On → Buy
09/03/2019 295.65% Barclays → $20 Initiates Coverage On → Overweight
08/27/2019 315.43% SunTrust Robinson Humphrey $20 → $21 Maintains Buy
08/07/2019 295.65% Keybanc → $20 Upgrades Sector Weight → Overweight
07/24/2019 275.87% Stifel $18 → $19 Upgrades Hold → Buy
07/02/2019 295.65% SunTrust Robinson Humphrey $19 → $20 Upgrades Hold → Buy
03/29/2019 216.52% Deutsche Bank $14 → $16 Maintains Hold
02/13/2019 355% Jefferies $18 → $23 Upgrades Hold → Buy
12/11/2018 246.19% Wells Fargo $13.5 → $17.5 Upgrades Underperform → Market Perform

What is the target price for Medical Properties Trust (MPW)?

The latest price target for Medical Properties Trust (NYSE: MPW) was reported by Wells Fargo on October 17, 2023. The analyst firm set a price target for $4.00 expecting MPW to fall to within 12 months (a possible -20.87% downside). 28 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Medical Properties Trust (MPW)?

The latest analyst rating for Medical Properties Trust (NYSE: MPW) was provided by Wells Fargo, and Medical Properties Trust maintained their underweight rating.

When is the next analyst rating going to be posted or updated for Medical Properties Trust (MPW)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.

Is the Analyst Rating Medical Properties Trust (MPW) correct?

While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a maintained with a price target of $7.00 to $4.00. The current price Medical Properties Trust (MPW) is trading at is $5.06, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment